lurasidone / Generic mfg. - LARVOL DELTA

Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder (clinicaltrials.gov) - P=N/A | N=155 | Completed | Sponsor: Dong-Wook Kim

New trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Lurasidone ameliorates doxorubicin-induced chemobrain in male Wistar rats: involvement of the hippocampal and prefrontal cortex CREB/BDNF/Glt-1 axis and glutamate homeostasis. (PubMed, Front Pharmacol) - "This study provides the first evidence that lurasidone mitigates doxorubicin-induced chemobrain. This neuroprotective effect is associated with the restoration of glutamate homeostasis and the upregulation of hippocampal and prefrontal CREB/BDNF/Glt-1 signaling, highlighting lurasidone as a promising therapeutic option for chemotherapy-induced cognitive impairment."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Oncology • BDNF • CASP3

Electroconvulsive Therapy Refusal in Severe Psychosis: Navigating Capacity, Surrogate Decision-Making, and Ethical Duty. (PubMed, Cureus) - "She was partially compliant with psychotropic therapy, including haloperidol, lorazepam, and lurasidone, but demonstrated limited improvement. This case highlights the enduring clinical and ethical complexities surrounding the use of ECT. It underscores the importance of evaluating capacity, engaging families in shared decision-making, and balancing the principles of autonomy and beneficence in the treatment of severe psychiatric illness."

Journal • Cardiovascular • CNS Disorders • Depression • Dyslipidemia • General Anxiety Disorder • Hypertension • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

A Summary for Non-Psychiatrists of the Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Guidelines for the Management of Schizophrenia. (PubMed, Med J Aust) - "A comprehensive yet tailored clinical assessment should be undertaken to identify treatable physical health comorbidities early, particularly for people with early psychosis. Pharmacotherapy should aim for the lowest effective dose with a tolerable and manageable adverse-effect profile (e.g., first-line pharmacotherapy with aripiprazole, brexpiprazole, cariprazine or lurasidone). Lifestyle interventions, particularly physical activity and multimodal lifestyle programmes, should be routinely offered to people with schizophrenia. Psychological and psychosocial interventions are essential components of care for people with schizophrenia, especially during the maintenance phase of illness. Clinicians should actively involve people with schizophrenia and their family, whānau and carers in shared decision-making. Comorbid psychiatric symptoms and conditions should be assessed and managed according to standard treatment approaches until more robust evidence base specific to..."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Broadband Near Infrared Spectroscopy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disorder (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Martin Lan

New P4 trial • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Antipsychotics and Sleep Architecture: Where Does Lurasidone Fit? (PubMed, Cureus) - "Dedicated sleep studies remain few, and long-term data using polysomnography, actigraphy, circadian biomarkers, and validated measures of daytime functioning are lacking. Further comparative studies are needed to determine whether lurasidone provides clinically meaningful sleep-related benefits beyond improvements attributable to treatment of the underlying psychiatric disorder."

Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Insomnia • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia • Sleep Disorder

Interim data from ENIGMA – TRS 1 study of evenamide as add on therapy to antipsychotic Standard of Care in patients with treatment resistant schizophrenia (TRS). Difficulties in performing TRS study with TRRIP criteria: the CRO experience (WFSBP 2026) - "One aspect of the ENIGMA – TRS 1 study assesses plasma concentrations of standard of care as selected antipsychotics: Aripiprazole, Brexpiprazole, Cariprazine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone and Ziprasidone for subjects treated with those antipsychotics with daily therapeutic doses meeting local product labels requirements and correlated those with minimal duration of 6 weeks treatment with any of those medications. As the study is performed in 20 countries worldwide major issues reside in getting approval by all regulatory approvals, languages use for the rating instruments as well as for the training of the raters. Based on hundreds of patients entering screening, a large proportion failed the screening phase because of lack of adequate concentration of the primary AP. Difficulties have been noticed in ensuring adequate documentation of previous AP failures."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

From Chromatographic Optimisation to Bioanalysis: HPLC System Comparison and HPLC-QTRAP-MS/MS Determination of Cariprazine and Lurasidone in Human Serum, Urine, and Saliva. (PubMed, Int J Mol Sci) - "The method was successfully applied for the determination of CAR and LUR in biological samples obtained from psychiatric patients. The findings suggest that saliva may be a non-invasive alternative for the quantification of free levels of investigated drugs, although further studies are required to clarify its relationship with plasma concentrations."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia

The Relative Infant Dose for Maternal Use of Drugs During Breastfeeding: Nuances in Derivation, Interpretation, and Application. (PubMed, J Clin Psychiatry) - "Examples of the RID are provided for ketamine and its active metabolite norketamine, lurasidone, and viloxazine. Readers need to be aware that there is more to the RID than just the arbitrary 10% cutoff."

Journal • Review

Lurasidone-Associated Urinary Retention in a Patient With Bipolar Affective Disorder: A Case Report. (PubMed, Case Rep Psychiatry) - "Despite dose reduction and addition of tamsulosin, symptoms of UR persisted and only resolved with cessation of lurasidone. This case underscores the need for clinicians to remain vigilant for UR in patients prescribed lurasidone, or other atypical antipsychotics, despite their generally favourable side effect profile. Early recognition and management are critical to prevent complications and ensure appropriate ongoing treatment of BPAD."

Journal • Bipolar Disorder • CNS Disorders

Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy (clinicaltrials.gov) - P3 | N=364 | Not yet recruiting | Sponsor: Bukwang Pharmaceutical

Monotherapy • New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Structure-Affinity Relationship Optimization of SYA16263 Yields New Ligands with Improved Receptor Affinity and Antipsychotic-Like Properties. (PubMed, ACS Omega) - "Thus, 35 and 36 have the potential to produce antipsychotic-like results in humans in a manner similar to lurasidone. Our future studies are planned to include preclinically evaluating pharmacological responses in specific genetic models to strengthen findings on antipsychotic effects."

Journal • ADHD (Impulsive Aggression) • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia • TNFSF12

Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment-Resistant Schizophrenia Patient. (PubMed, Case Rep Psychiatry) - "The beneficial effect of lurasidone on TD is hypothesized to be related to various receptor interactions of the current treatment, as well as 5-HT2A antagonism and preferential modulation of dopamine turnover in the prefrontal cortex rather than the striatum, as also observed with clozapine. Further studies are warranted to elucidate the underlying mechanisms of this phenomenon."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

Lurasidone hydrochloride-loaded microparticle-based long-acting injectable: formulation optimisation, characterisation, and payload release kinetics-a proof of concept study. (PubMed, J Microencapsul) - "The real-time study showed 80.26 ± 3.84% drug release within 90 days. Overall, the results of this research work furnished a strong basis for further development of lurasidone hydrochloride microparticle-based long-acting injectables at a large scale."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. (PubMed, BMJ) - "The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase. (PubMed, Ther Adv Psychopharmacol) - "Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. These findings suggest a potential role of dopamine D4 receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings."

Adverse events • Journal • PK/PD data • CNS Disorders • Epilepsy • Psychiatry • Schizophrenia

Case Report: Early-onset psychosis as a sentinel manifestation of 3q29 deletion syndrome in an adolescent with neurodevelopmental disorders. (PubMed, Front Child Adolesc Psychiatry) - "Combination therapy with lurasidone and olanzapine led to sustained clinical stabilization over a one-year follow-up period, allowing gradual dose adjustment and functional reintegration through adapted educational and recreational activities. Early-onset psychotic symptoms in adolescents with neurodevelopmental comorbidities may represent a critical clinical indicator of underlying pathogenic copy number variants, including 3q29 deletion syndrome, even in the absence of highly recognizable dysmorphic features. Increased clinical awareness may facilitate consideration of early genetic testing in this clinical profile to support precision-informed diagnostic evaluation, treatment planning and multidisciplinary management."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Cardiovascular • CNS Disorders • Developmental Disorders • Genetic Disorders • Heart Failure • Mental Retardation • Psychiatry • Schizophrenia

Impact of nutritional factors on the pharmacokinetics of antipsychotics - a systematic review. (PubMed, Psychiatry Res) - "Nutritional factors are a significant source of PK variability in antipsychotic treatment. The results underscore the necessity of standardized administration guidelines (e.g., "take with food" for ziprasidone or "fasted" for amisulpride) to ensure predictable plasma levels and optimize therapeutic outcomes in clinical practice."

Journal • PK/PD data • Review • CNS Disorders • Psychiatry

A Case of Meige Syndrome in a Pediatric Patient With Schizophrenia. (PubMed, Clin Case Rep) - "We stopped giving him the same medications that had been used during his previous hospitalizations (risperidone, olanzapine, aripiprazole, lurasidone, and paliperidone, paliperidone palmitate (a long-acting injectable), asenapine, and blonanserin). We then started giving him clozapine, gradually increasing the dose to 125 mg. Following this treatment intervention, the dystonic symptoms resolved completely, and the psychiatric symptoms stabilized."

Journal • CNS Disorders • Dystonia • Movement Disorders • Pediatrics • Psychiatry • Schizophrenia

Transient, dose-dependent QTc prolongation with lurasidone in an older woman with schizophrenia: A case report. (PubMed, Indian J Psychiatry) - No abstract available

Journal • CNS Disorders • Psychiatry • Schizophrenia

Probable Serotonin Syndrome Precipitated by the Addition of Trazodone to Lurasidone and Valproic Acid: A Case Report. (PubMed, Sante Ment Que) - "Besides trazodone, the patient was prescribed valproic acid, lurasidone, estradiol, dexlansoprazole and spironolactone. Although most cases of SS associated with trazodone involve selective serotonin reuptake inhibitor antidepressants, this case report suggests that the combination of trazodone, lurasidone and valproic acid can lead to excessive serotoninergic activity via serotonin reuptake inhibition, 5-HT1A partial agonism and increased central serotoninergic neurotransmission. Therefore, clinicians should exercise caution when trazodone is combined with a second-generation antipsychotic and valproic acid."

Journal • CNS Disorders • Insomnia • Movement Disorders • Sleep Disorder

Successful Treatment of Rapid Cycling Bipolar Disorder With Lurasidone, Clozapine, and Valproate: A Case Report. (PubMed, Bipolar Disord) - No abstract available

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Case Report: Lurasidone-Induced Type 2 Brugada Pattern in a Pediatric Patient. (PubMed, Clin Pract Cases Emerg Med) - "In syncope cases, an ECG is crucial for identifying arrhythmogenic causes, including Brugada syndrome. This case highlights an ECG suggestive of Brugada syndrome with negative pharmacological tests and resolution post-discontinuation of the offending agent. Emergency physicians should be vigilant for Brugada and long QT syndromes in patients on antipsychotic medications."

Journal • Autism Spectrum Disorder • Cardiovascular • CNS Disorders • Critical care • Genetic Disorders • Pediatrics

Acute Laryngeal Dystonia Mimicking Anaphylaxis Following Antipsychotic Initiation: A Case Report. (PubMed, Case Rep Psychiatry) - "Rapid resolution following intramuscular benztropine supported the diagnosis of ALD as the most likely diagnosis...It also illustrates how anchoring bias and diagnostic momentum may contribute to recurrent misclassification. Early recognition of laryngeal dystonia can prevent unnecessary treatment, reduce the risk of airway compromise, and improve diagnostic accuracy."

Journal • Allergy • Cardiovascular • CNS Disorders • Dysphonia • Dystonia • Hypotension • Movement Disorders • DRD2

Expert Consensus on the Use of Lurasidone for Bipolar I Depression in Asian Patients. (PubMed, Alpha Psychiatry) - "Caution was advised when prescribing lurasidone during pregnancy, particularly in the first trimester. This expert consensus provides practical guidance for the use of lurasidone in the treatment of bipolar I depression in Asian patients, complementing existing treatment guidelines and addressing dosing strategies, side effect management, and use in special populations."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry